PubRank

Peter Browett

Author PubWeight™ 23.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012 2.21
2 A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002 1.89
3 Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004 1.81
4 Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004 1.57
5 The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011 1.50
6 Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res 2003 1.43
7 Bone metabolism during long-term treatment with imatinib. Leuk Lymphoma 2013 1.40
8 Private umbilical cord blood banking: a biological insurance of dubious future benefit! N Z Med J 2005 1.39
9 Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007 1.15
10 Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 2009 1.14
11 Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009 0.96
12 Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006 0.94
13 Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Br J Haematol 2010 0.91
14 Inflammatory pseudotumor-like follicular dendritic cell tumor of liver and spleen: granulomatous and eosinophil-rich variants mimicking inflammatory or infective lesions. Am J Surg Pathol 2014 0.88
15 Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 2011 0.88
16 Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol 2012 0.83
17 Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res 2004 0.82
18 FISH detection of PML-RARA fusion in ins(15;17) acute promyelocytic leukaemia depends on probe size. Biomed Res Int 2013 0.81
19 Imatinib mesylate does not increase bone volume in vivo. Calcif Tissue Int 2010 0.79
20 A +8 (-->CT) mutation within the 5' untranslated region of beta-globin down-regulates the mRNA transcription. Hemoglobin 2008 0.77
21 High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. Haematologica 2008 0.75
22 Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six cases. Leuk Lymphoma 2014 0.75
23 Paternalism in practice: informing patients about expensive unsubsidised drugs. J Med Ethics 2010 0.75
24 Hb Feilding [β12(A9)Thr → Pro; HBB: c.37A>C]: a novel unstable β-globin chain variant. Hemoglobin 2015 0.75
25 A unique case of neural amyloidoma diagnosed by mass spectrometry of formalin-fixed tissue using a novel preparative technique. Amyloid 2011 0.75
26 A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. Am J Hematol 2014 0.75